Zolmitriptan transdermal - Zosano Pharma

Drug Profile

Zolmitriptan transdermal - Zosano Pharma

Alternative Names: M 207; Triptan microneedle patch - Zosano Pharma; Triptan patch - Zosano Pharma; Triptan transdermal - Zosano Pharma; ZP triptan -Zosano Pharma; ZP-triptan

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Zosano Pharma
  • Class Antimigraines; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Migraine

Most Recent Events

  • 01 Mar 2017 The safety study is expected to initiate following completion of the Zotrip trial, in the second half of 2017
  • 15 Feb 2017 Efficacy and adverse events data from the phase II/III Zotrip trial in Migraine released by Zosano Pharma
  • 13 Feb 2017 Zosano Pharma completes the Zotrip trial in Migraine in USA (Transdermal) (NCT02745392)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top